Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKrm22 Plc Regulatory News (KRM)

Share Price Information for Krm22 Plc (KRM)

Share Price is delayed by 15 minutes
Get Live Data
32.50    0.00 (0.00%)
Bid:
32.00
Ask:
33.00
Spread: 1.00 (3.125%)
Market Cap: £19.28m
KRM Live PriceLast checked at - London Stock Exchange

Intraday Krm22 Plc Share Chart

Directorate Changes

30 Apr 2019 07:00

RNS Number : 4672X
KRM22 PLC
30 April 2019
 

 

KRM22 plc

 

("KRM22" or the "Company")

 

Directorate Changes

 

KRM22 plc, (AIM: KRM) the technology and software investment company that focuses on risk management for capital markets, announces the appointment of Garry Jones as an independent Non-Executive Director of the Company. Mr Jones will replace David Ellis, Independent Non-Executive Director, who notified the Board of his intention to step down from the Board with immediate effect after being with the Company since its IPO in early 2018. Mr Ellis is stepping down to focus on other business commitments and a relocation to the United States.

 

Garry has over 35 years' experience in financial services and has been CEO of three of the largest derivatives and OTC exchanges in Europe: BrokerTec, LIFFE and the London Metal Exchange ("LME"). He has contributed to the business change, growth, and globalisation in exchanges, driving the momentum behind electronic trading and increased efficiency in the post trade environment via straight-through clearing.

 

Garry was part of the initial management team at BrokerTec, becoming CEO and President of BrokerTec Europe, before running ICAP Electronic Broking (Europe) - the forerunner of NEX. Brokertec became the largest global OTC trading platform, with major strengths in government bonds and repo. He joined NYSE Euronext in 2005 and was Global Head of Derivatives (overseeing derivatives markets in Europe and the USA) and CEO of the NYSE LIFFE exchange. In 2013 he became Co-Head of Markets at HKEX and CEO of the LME, based in London but with an office in Hong Kong and spending considerable time in Asia, with a major focus on China. He left HKEX in 2017, remaining an advisor to the company until 2018.

 

Garry was a founder member of the Futures and Options Association's European Industry Council and was a member of the UK's Financial Services Authority senior Practitioner Panel that advised on new policy initiatives under the UK's former regulatory regime. He was on the Board of The Federation of European Security Exchanges and alternate Board member of the World Federation of Exchanges. He served as a Director of The London Clearing House as well as the Qatar Exchange.

 

With the resignation of David and the appointment of Garry, the Board remains comprised of three independent Non-Executive Directors and the three Executive Directors.

 

Keith Todd, Executive Chairman commented:

 

"All the team thank warmly David for his valuable contributions since KRM22's IPO and we wish him well with his new focus in the USA.

 

We are delighted to welcome Garry to the KRM22 Board. Garry brings deep knowledge and expertise of capital markets and has managed risks himself throughout his career in multiple ways. Garry's decision to join the KRM22 Board reflects his view of how important the KRM22 Global Risk Platform is and the opportunity we have to help customers reduce the cost and complexity of managing their risks. All the team welcome him warmly."

 

 

The following information is disclosed in relation to Garry Peter Jones, age 60, pursuant to Schedule Two paragraph (g) and Rule 17 of the AIM Rules for Companies:

 

Current Directorships / Partnerships:

 

Horatio Ventures

 

Previous Directorships / Partnerships (held in the past five years)

 

London Metal Exchange

LME Clear

HKEX Investment (UK)

LME Holding

 

 

Mr. Jones currently holds 176,471 ordinary shares in the Company, representing 0.97 per cent. of the issued share capital of the Company.

 

There is no further information to be disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

 

KRM22 plc

InvestorRelations@krm22.com

Keith Todd CBE, Executive Chairman and CEO

Karen Bach, COO

finnCap Ltd (Nominated Adviser and Sole Broker)

+44 (0)20 7220 0500

Carl Holmes / Kate Bannatyne - Corporate Finance

Alice Lane / Sunila de Silva - ECM

 

About KRM22 plc

KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has been established with the objective of creating value for its investors through the investment in, and subsequent growth and development of, target companies in the technology and software sector, with a focus on risk management in capital markets.

Through its investments and the Global Risk Platform, KRM22 helps capital market companies reduce the cost and complexity of risk management. The Global Risk Platform provides applications to help address firms' regulatory, market, technology and operations risk challenges and to manage their entire enterprise risk profile.

 

Capital markets companies' partner with KRM22 to optimize risk management systems and processes, improving profitability and expanding opportunities to increase portfolio returns by leveraging risk as alpha.

 

KRM22 PLC is listed on AIM and the Group is headquartered in London, with offices in several of the world's major financial centres.

 

See more about KRM22 at KRM22.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAPGUACCUPBGQB
Date   Source Headline
26th May 20263:24 pmRNSHolding(s) in Company
26th May 20262:25 pmRNSHolding(s) in Company
22nd May 20267:00 amRNSDirector Dealings
20th May 202611:19 amRNSDirector Dealings
20th May 20267:00 amRNSNotice of AGM and Posting of Annual Report
13th May 20267:00 amRNSFinal Results
29th Jan 20267:00 amRNSTrading Update
7th Jan 20267:00 amRNSAppointment of Director
20th Nov 20254:12 pmRNSTR-1
11th Nov 20257:00 amRNSIssue of Equity
10th Nov 20259:28 amRNSHolding(s) in Company
5th Nov 20251:05 pmRNSResult of GM
15th Oct 20257:00 amRNSResult of Placing
14th Oct 20254:50 pmRNSProposed Placing and Subscription
17th Sep 20257:00 amRNSInterim Results
7th Aug 20257:00 amRNSTrading Update
21st Jul 20257:00 amRNSIssue of Equity
27th Jun 20252:10 pmRNSResult of AGM
6th Jun 20257:00 amRNSDirector Dealing
2nd Jun 20257:00 amRNSIssue of Restricted Stock Units
30th May 20257:00 amRNSNotice of AGM and Posting of Annual Report
21st May 20257:00 amRNSDirector Dealing
19th May 20257:00 amRNSFinal Results
29th Apr 20257:00 amRNSFacility Amendment
7th Apr 20257:00 amRNSNew Customer Contracts
1st Apr 20257:00 amRNSFacility Amendment
18th Mar 20257:00 amRNSIssue of Equity
4th Mar 20257:00 amRNSNew Customer Contract
13th Feb 20255:00 pmRNSDirector Dealing
22nd Jan 20257:00 amRNSTrading Update
10th Jan 20257:00 amRNSIssue of Equity
23rd Dec 20247:00 amRNSLoan Facility Amendment
15th Oct 20247:00 amRNSIssue of Equity
25th Sep 20247:00 amRNSInterim Results
3rd Sep 20247:00 amRNSChange of Registered Office
29th Aug 20247:00 amRNSNew Customer Contract
22nd Aug 202410:00 amRNSGrant of Options and Director/PDMR Shareholding
19th Aug 20247:00 amRNSIssue of Equity
18th Jul 20247:00 amRNSHalf Year Trading Update
21st Jun 202412:49 pmRNSResult of AGM
29th May 20247:00 amRNSNotice of AGM and Posting of Annual Report
22nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSDirector Dealings
15th Apr 20247:00 amRNSNew Customer Contract
10th Apr 20247:00 amRNSIssue of Equity
7th Mar 20247:00 amRNSBoard Changes
21st Feb 20247:00 amRNSTrading Update
1st Dec 20237:00 amRNSIssue of Restricted Stock Units
26th Sep 20237:00 amRNSInterim Results
27th Jul 202311:48 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.